[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550726":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":39,"responsibleParty":62,"collaborators":65,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":12,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":12,"enrollmentInfo":77,"targetDuration":12,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":12,"overallStatus":90,"whyStopped":12,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Leeds","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Arm","NO_INTERVENTION","Control Arm: NHS standard care pathway delivered.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention Arm","EXPERIMENTAL","Intervention Arm: Professional Oral Health Care (POHC) referred to as PRIOR \\[Proactive Intensive Oral Review \\& Treatment\\] prior to chemotherapy.",[18],"Procedure: PRIOR [Proactive Intensive Oral Review & Treatment]",[20],{"type":21,"name":22,"description":16,"armGroupLabels":23,"otherNames":12},"PROCEDURE","PRIOR [Proactive Intensive Oral Review & Treatment]",[14],[25],{"name":26,"affiliation":27,"role":28},"Zaid Ali, BChD","LTHT","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":12,"email":34},"Sue H Pavitt, PhD","CONTACT","+44 7939 014 659","s.pavitt@leeds.ac.uk",{"name":36,"role":32,"phone":37,"phoneExt":12,"email":38},"Anna Nielsen","+44 7948 776456","a.l.nielsen@leeds.ac.uk",[40],{"facility":41,"status":12,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Dental Translational & Clinical Research Unit (DenTCRU)","Leeds","West Yorkshire","LS29LU","United Kingdom","UK",{"type":48,"coordinates":49},"Point",[50,51],-1.54785,53.79648,{"lat":51,"lon":50},[54,57,61],{"name":55,"role":32,"phone":56,"phoneExt":12,"email":34},"Sue Pavitt, PhD","+44 7939 014659",{"name":58,"role":32,"phone":59,"phoneExt":12,"email":60},"Nuria Navarro-Coy","+44 7967 786733","n.navarro-coy@leeds.ac.uk",{"name":26,"role":28,"phone":12,"phoneExt":12,"email":12},{"type":28,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Sue Pavitt","Professor",[66],{"name":67,"class":6},"The Leeds Teaching Hospitals NHS Trust","100550726","prospect-prior-2-chemo-prior-dental-intervention-before-chemo-to-reduce-chemotherapy-complications-100550726",false,"NCT06450821","PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications","PROSpECT-PRIOR-2-CHEMO: A Feasibility RCT of Novel Dental Intervention PRIOR[Proactive Intensive Oral Review & Treatment] in Patients Scheduled for Chemotherapy for Myeloma-ASCT & Hematological Cancers to Mitigate Chemotherapy Complications","Inclusion Criteria (mod-high\u002Frisk trial participants):\n\n* Adults (≥ 18years) with scheduled Chemotherapy. Specifically, patients who meet the following diagnosis and treatment window requirements:\n\n  * Myeloma- Autologous Stem Cell Transplantation (ASCT) before high-dose myeloablative CT.\n  * Haematological cancers suitable for Allografts Stem Cell Transplant (SCT) before CT\n* Moderate \u002F High Oral Health Risk Assessment - any one of the following:\n\n  * Clinical evidence of caries (2+ teeth)\n  * Clinical evidence on soft and hard tissue examination of infection, sinus, swelling or tenderness\n  * BPE code 3-4 in any remaining sextant\n  * BPE code 1-2 with \\>30% BOP\n* The patient is fully informed, has received PIS (patient information sheet) and considered during a 'cooling-off' period, is competent to consent, and is able to comply with minimum attendance requirements\n\nExclusion Criteria:\n\n* Have a history of head and neck radiotherapy\n* Have been treated with Denusomab, Bevacizumab, Sunitinib or Aflibercept within 9 months of the MDT date.\n* Insufficient teeth \\[defined as \\\u003C2\\]\n* Are incapable of providing informed written consent\n* Are unable to comply with minimum attendance requirements","ALL","18 Years",{"count":78,"type":79},60,"ESTIMATED","INTERVENTIONAL",[82],"NA","The aim of this feasibility trial is to determine if it is safe and feasible to treat oral health diseases in people with haematological cancers before they start their chemotherapy to reduce complications and disruption to planned chemotherapy dose or schedule.",[85,86,87,88,89],"Oncology","Periodontitis","Myeloma","Oral Mucositis","Febrile Neutropenia","NOT_YET_RECRUITING","2024-06-04",{"date":93,"type":94},"2024-06-10","ACTUAL",{"date":96,"type":79},"2024-07",{"date":98,"type":79},"2026-10",{"name":5,"class":6},1]